Outlook Therapeutics Secures FDA Approval For LYTENAVA™

About this update from Outlook Therapeutics, Inc.

On July 24, 2026 , Outlook Therapeutics , Inc. announced that the FDA approved LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (known as “nAMD” or “wet AMD”), marking the first FDA-approved ophthalmic formulation of bevacizumab in the United States . According to Outlook, bevacizumab has long been used off label in retina care through repackaged oncology formulations, but LYTENAVA™ is the first formulation specifically developed and approved for intravitreal ophthalmic use. Outlook also announced that the product is expected to receive 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act (“BPCIA”). Outlook is preparing for commercial launch and expects to make LYTENAVA™ available to patients before the end of the year. Mr Emma Murray Goodwin Procter LLP The New York Times Building 620 Eighth Avenue New York NY 10018 UNITED STATES Tel: 212813 8800 E-mail: [email protected] URL: www.goodwinlaw.com © Mondaq Ltd, 2026 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

View stock analysis, news, and events for Outlook Therapeutics, Inc.